Jakap Koo - 12 May 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Reporting relationship: Director
Issuer ticker: APUS
Reported as of: 12 May 2025
Net transaction value: +$56,715
SEC form: 4
Accepted by SEC: 14 May 2025, 17:58:18 UTC
Prior SEC filing: 08 May 2025
Next SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact

Key filing fact

Jakap Koo filed Form 4 for Apimeds Pharmaceuticals US, Inc. (APUS) on 14 May 2025.

Key facts

This page summarizes Jakap Koo's Form 4 filing for Apimeds Pharmaceuticals US, Inc. (APUS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 May 2025, 17:58.

Change

Previous filing in this sequence was filed on 08 May 2025.
Current net transaction value: +$56,715.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002041972 Primary reporting owner

Koo Jakap

Relationship: Director
Address: C/O APIMEDS PHARMACEUTICALS US, INC., 2 EAST BROAD STREET, 2ND FLOOR, HOPEWELL
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Signature date: 14 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APUS transaction

Common Stock, par value $0.01 per share

Purchase

Transaction value: $56,715
Shares: +28,500
Change %: +4.6%
Price: $1.99
Shares after: 643,885
Date: 12 May 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

Footnote F2

These shares were sold in multiple transactions at prices ranging from $1.9774 to $2.2000, inclusive.